Epigenetic Priming with Oral Decitabine/Cedazuridine Combined with Nivolumab in Unresectable or Metastatic Mucosal Melanoma: Clinical and Correlative Findings from a Phase Ib/II Trial. (PubMed, Cancers (Basel)) - Oct 17, 2026 - P1/2 | "Although two partial responses were observed, the small sample size and wide confidence interval preclude conclusions regarding efficacy. These findings support future biomarker-integrated studies evaluating epigenetic immune-priming combinations in mucosal melanoma, with prospective optimization of dose, schedule, and treatment setting."
IO biomarker • Journal • P1/2 data • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor
|
|
Cheng-Chang Wu; Claire M Muckle; Dexiang Gao; Elizabeth N Katsnelson; Jessica S W Borgers; Kasey L Couts; Kimberly R Jordan; Luke Mantle; Martin D McCarter; Phaedra A Whitty; Richard P Tobin; Sapna P Patel; Theresa M Medina; William A Robinson
|